Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | Tralokinumab (STRATOS1) | Severe, uncontrolled asthma | Phase 3 | Trial Discontinued | Subcutaneous | Respiratory |
| AstraZeneca PLC | AZD1222 (D8110C00001) | COVID-19 vaccine | Phase 3 | Trial Discontinued | Intramuscular | COVID-19 |
| AstraZeneca PLC | FASENRA (Benralizumab) - (TERRANOVA) | COPD | Phase 3 | Trial Discontinued | Subcutaneous | Respiratory |
| AstraZeneca PLC | Imfinzi (durvalumab) - (ADJUVANT BR.31) | Early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | Truqap - (CAPItello-290) | Metastatic triple-negative breast cancer | Phase 3 | Data Released | oral | Oncology |
| Astria Therapeutics Inc. | Edasalonexent (CAT-1004) | Duchenne muscular dystrophy (DMD) | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Astria Therapeutics Inc. | Navenibart (STAR-0215) - (ALPHA-ORBIT) | Hereditary angioedema (HAE), healthy volunteers | Phase 3 | Ongoing | Subcutaneous | Genetic Disorder |
| Astria Therapeutics Inc. | Navenibart (STAR-0215) - (ALPHA-SOLAR) | Hereditary Angioedema | Phase 3 | Data Released | Subcutaneous | Genetic Disorder |
